CNTX (Context Therapeutics) Total Equity: $52.20 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTX Context Therapeutics Inc CNTX
24 GF Score
Price $0.58
! 1 Warning Sign
View Full Analysis

What is Context Therapeutics Total Equity?

Context Therapeutics CNTX -1.17% 24 Total Equity is $52.20 Mil as of Mar. 2026. GuruFocus rates CNTX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Context Therapeutics's total equity for the quarter that ended in Mar. 2026 was $52.20 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Context Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Context Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics Total Equity Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 48.27 34.76 11.87 95.27 60.47

Context Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.98 82.54 73.17 60.47 52.20
CNTX
24GF Score
Context Therapeutics Inc CNTX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Context Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Context Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=68.494-8.02
=60.47

Context Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=58.859-6.657
=52.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $52.20 Mil mean?
Context Therapeutics (CNTX) has a Total Equity of $52.20 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Context Therapeutics and its competitors.
Is Context Therapeutics' Total Equity too high?
Context Therapeutics' current Total Equity is $52.20 Mil. Overall, Context Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' Total Equity compare to INKT and XLO?
Context Therapeutics' Total Equity of $52.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Context Therapeutics and its competitors. Context Therapeutics's current Total Equity is $52.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current Total Equity of $52.20 Mil. The current Total Equity is $52.20 Mil. Context Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current Total Equity is $52.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Context Therapeutics Business Description

Other Exchanges 6K9:Germany
Address 2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
24GF Score

Get the complete analysis for CNTX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price